AbbVie’s Drug Upadacitinib Shows Positive Phase 3 Results for Severe Alopecia Areata Treatment

AbbVie Inc. (NYSE:ABBV) is one of the most undervalued quality stocks to buy according to hedge funds. On July 30, AbbVie announced positive topline results from Study 2 of its pivotal Phase 3 UP-AA clinical program, which is evaluating the safety and efficacy of upadacitinib (RINVOQ) for treating severe alopecia areata/AA in adults and adolescents.

In this study, both daily doses of upadacitinib, 15 mg and 30 mg, met the primary endpoint. Key secondary endpoints were also successfully met. The safety profile observed in the study was consistent with what has been seen in the approved indications for RINVOQ. The most common side effects were acne, nasopharyngitis, and upper respiratory tract infections.

A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist.

Treatment-emergent serious adverse events occurred in 1.4% of patients on the 15 mg dose and 2.8% on the 30 mg dose, with no serious adverse events in the placebo group. No adjudicated major cardiovascular events/MACE, malignancies, or deaths were reported. One adjudicated venous thromboembolism was reported in a patient on the 15 mg dose who had multiple risk factors. The results from the parallel replicate study/Study 1 of the Phase 3 UP-AA program are also expected in Q3 2025.

AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that researches, develops, manufactures, commercializes, and sells medicines and therapies worldwide.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.